Mineralys Therapeutics Stock (NASDAQ:MLYS)

Forecast Ownership Financials Chart Transcripts

Previous Close

$31.12

52W Range

$22.30 - $47.65

50D Avg

$27.16

200D Avg

$29.49

Market Cap

$2.69B

Avg Vol (3M)

$1.13M

Beta

0.68

Div Yield

MLYS Company Profile

Mineralys Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing medicines to target diseases driven by abnormally elevated aldosterone. Its clinical-stage product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor that are initially developing for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone, including hypertension and chronic kidney disease. The company was founded by Brian Taylor Slingsby on May 31, 2019 and is headquartered in Radnor, PA.

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

Country

Employees

IPO Date

Feb 10, 2023

Website

MLYS Performance

MLYS Financial Summary

	Dec 25	Dec 24	Dec 23
Revenue	-	-	-
Operating Income	$-170.60M	$-192.40M	$-84.66M
Net Income	$-154.65M	$-177.81M	$-71.90M
EBITDA	$-170.60M	$-192.36M	$-84.66M
Basic EPS	$-2.29	$-3.66	$-1.99
Diluted EPS	$-2.29	$-3.66	$-1.99

Fiscal year ends in Dec 25 | Currency in USD

Latest Earnings Call Transcripts

Q2 26Aug 11, 26 | 4:30 PM

Q1 26May 06, 26 | 4:30 PM

Q4 25Mar 12, 26 | 4:30 PM

Peer Comparison

Ticker	Company
BEAM	Beam Therapeutics Inc.
ADPT	Adaptive Biotechnologies Corporation
IDYA	IDEAYA Biosciences, Inc.
ZLAB	Zai Lab Limited
RXRX	Recursion Pharmaceuticals, Inc.
AGIO	Agios Pharmaceuticals, Inc.
CDTX	Cidara Therapeutics, Inc.
SRRK	Scholar Rock Holding Corporation